To the Editor: In their summary statements
of the evidence, Dr Straus and colleagues1 sometimes
failed to clarify the findings of single, groundbreaking randomized clinical
trials, which may be more important than meta-analyses of multiple smaller
studies. An example is their passing mention of the European Secondary Prevention
Study 2 (ESPS-2), the largest study of aspirin and dipyridamole in secondary
Kirshner HS. Reducing the Risk of Stroke. JAMA. 2003;289(15):1927–1929. doi:10.1001/jama.289.15.1927
Customize your JAMA Network experience by selecting one or more topics from the list below.